TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2017

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.

Helena A Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.